zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
budenofalk 3 mg kapszula
dr. falk pharma gmbh - budezonid -
apulein kenőcs
richter gedeon nyrt. - budezonid -
neo-rinactive 100 szuszpenziós orrspray
alcon cusi s.a. - budezonid -
neo-rinactive szuszpenziós orrspray
alcon cusi s.a. - budezonid -
pulmicort 50 mcg/adag inhalációs aeroszol
astrazeneca ab - budezonid -
pulmicort 200 mcg/adag inhalációs aeroszol
astrazeneca ab - budezonid -
rhinocort 50 mcg/adag orrspray
astrazeneca ab - budezonid -
pulmicort turbuhaler 200 mcg/adag por inhalációhoz
astrazeneca ab - budezonid -
pulmicort turbuhaler 400 mcg/adag por inhalációhoz
astrazeneca ab - budezonid -